Sarepta Therapeutics: A Strong Opportunity Amidst The Panic
Sarepta Therapeutics is trading at a huge discount to previous enterprise value, with significant upside potential as the situation stabilizes in the near term. ELEVIDYS may be able to regain the non-ambulatory segment in the future, leading to further opportunity. Company restructuring sets up a realistic shot of turnaround.
Sarepta Sells Arrowhead Stake to Fund Milestone Payment
Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.
Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside
For Sarepta Therapeutics NASDAQ: SRPT, 2025 has been nothing short of an unmitigated disaster. The firm owns the only Food and Drug Administration (FDA)-approved gene therapy for the treatment of Duchenne muscular dystrophy (DMD), known as ELEVIDYS.
Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries
SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.
Sarepta Therapeutics (SRPT) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Sarepta Therapeutics (SRPT) Tops Q2 Earnings and Revenue Estimates
Sarepta Therapeutics (SRPT) came out with quarterly earnings of $2.02 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.07 per share a year ago.
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.
Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Opinion | On Sarepta, a Welcome FDA Reversal
After our editorial, the agency relents to allow a Duchenne treatment.
Sarepta finally gets some good news: A patient death wasn't its DMD drug's fault.
Sarepta Therapeutics' stock was soaring Tuesday after the FDA recommended lifting the pause on the company's Duchenne muscular dystrophy drug, but analysts worry it will take time for patients and doctors to feel safe using it.
Sarepta shares surge after FDA lifts pause on muscular dystrophy treatment
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares jumped 25% at the open on Tuesday after the US Food and Drug Administration recommended the company lift a voluntary pause on shipments of its gene therapy ELEVIDYS for ambulatory Duchenne muscular dystrophy (DMD) patients. The regulator's move follows its determination that the death of an eight-year-old patient in Brazil, which had prompted a temporary halt, was unrelated to the therapy.
Sarepta: SRPT Stock To $40?
Sarepta Therapeutics is trading around $19 in extended hours following the FDA's decision to remove the pause on Elevidys, marking a critical turning point for the beleaguered biotech. This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially double from current levels to around $40 after its dramatic fall from levels of $170.
